-  INCLUSION CRITERIA:

          -  Gastric/GEJ cancer Cohort:

               -  Participants must have metastatic or unresectable locally advanced Gastric/GEJ
                  cancer that has been histologically confirmed.

               -  Participants must have measurable disease by RECISTv1.1.

               -  Participants must have received or been ineligible to receive first line systemic
                  chemotherapy for Gastric/GEJ cancer. Participants with HER2 positive disease must
                  have received HER2-targeted therapy.

          -  Head and neck squamous cell carcinoma Cohort

               -  Participants must have metastatic or unresectable locally advanced HNSCC that has
                  been histologically confirmed.

               -  Participants must have measurable disease by RECISTv1.1.

               -  Participants must have received or been ineligible to receive first-line systemic
                  chemotherapy and must have received systemic anti-PD-1 therapy (in the first-line
                  or subsequent-line setting).

          -  Age >=18 years. Because no dosing or adverse event data are currently available on the
             use of this investigation combination therapy in participants <18 years of age,
             children are excluded from this study, but will be eligible for future pediatric
             trials.

          -  ECOG performance status <2

          -  Participants must have adequate organ and marrow function as defined below:

               -  leukocytes greater than or equal to 3,000/mcL

               -  absolute neutrophil count greater than or equal to 1,500/mcL

               -  platelets greater than or equal to 100,000/mcL

               -  total bilirubin within normal institutional limits

               -  AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of
                  normal

               -  creatinine Creatinine within 1.5X upper limit of normal institutional limits

          -  Participants with treated brain metastases are eligible if follow-up brain imaging
             after central nervous system (CNS)-directed therapy shows no evidence of progression.

          -  Participants with new or progressive brain metastases (active brain metastases) or
             leptomeningeal disease are eligible if the treating physician determines that
             immediate CNS specific treatment is not required and is unlikely to be required during
             the first 7 weeks of therapy.

          -  Participants with a history of hepatitis C virus (HCV) infection must have been
             treated and cured. For participants with HCV infection who are currently on treatment,
             they are eligible if they have an undetectable HCV viral load.

          -  Participants on therapeutic anticoagulation with warfarin must have an international
             normalized ratio (INR) that is within target range for their condition at the time of
             enrollment.

          -  The effects of PD-L1 t-haNKs with N-803 and pembrolizumab on the developing human
             fetus are unknown. For this reason and because these investigational agents
             teratogenicity is unknown, women of child-bearing potential and men must agree to use

        adequate contraception (hormonal or barrier method of birth control; abstinence) prior to
        study entry for the duration of study participation and for at least 4 months after last
        dose of study drug pembrolizumab.

        -Ability of subject to understand and the willingness to sign a written informed consent
        document.

        EXCLUSION CRITERIA:

          -  Participants who are receiving any other investigational agents or concurrent
             anticancer treatment. Palliative radiotherapy is allowed.

          -  Participants with concurrent use of systemic steroids (within 10 days of enrollment),
             except for physiologic doses of systemic steroid replacement or local (topical, nasal,
             intraarticular or inhaled) steroid use.

          -  Participants with active systemic autoimmune disease (e.g., lupus erythematosus,
             rheumatoid arthritis, Addison s disease, autoimmune disease associated with lymphoma,
             inflammatory bowel disease). Participants with autoimmune endocrine disorders
             controlled with medical management (e.g. thyroid disorders, type 1 diabetes, or
             adrenal insufficiency) will not be excluded

          -  Participants with a history of grade 3 or higher immune-related adverse events
             attributed to pembrolizumab or other anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy.
             This exclusion does not apply to participants with permanent endocrine insufficiencies
             (e.g. adrenal insufficiency or hypothyroidism) under satisfactory medical management.
             Additionally, participants with grade 2 adverse events attributed to these classes of
             agents will be excluded with the exception of rash, transient hyperthyroidism,
             transient liver enzyme abnormalities or other transient events that resolved without
             steroids or immunomodulatory agents.

          -  HIV or HBV infection due to unknown effect of PD-L1 targeting via a CAR or N-803 in
             these chronic viral infections.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris,
             uncontrolled serious cardiac arrhythmia, clinically significant coagulopathy or
             psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Pregnant women are excluded from this study because PD-L1 targeting via a CAR has
             unknown potential for teratogenic or abortifacient effects. Because there is an
             unknown but potential risk for adverse events in nursing infants secondary to
             treatment of the

        mother with PD-L1 targeting via a CAR and N-803, breastfeeding should be discontinued if
        the mother is treated on this study for the duration of study participation and for at
        least 4 months after last dose of any study drug.